Policy statement--postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia.

Abstract

The purpose of this revised statement is to review current information on the use of postnatal glucocorticoids to prevent or treat bronchopulmonary dysplasia in the preterm infant and to make updated recommendations regarding their use. High-dose dexamethasone (0.5 mg/kg per day) does not seem to confer additional therapeutic benefit over lower doses and is not recommended. Evidence is insufficient to make a recommendation regarding other glucocorticoid doses and preparations. The clinician must use clinical judgment when attempting to balance the potential adverse effects of glucocorticoid treatment with those of bronchopulmonary dysplasia.

• Authors: Kristi L Watterberg, American Academy of Pediatrics. Committee on Fetus and Newborn
• Journal: Pediatrics (Pediatrics) Vol. 126 Issue 4 Pg. 800-8 (Oct 2010) ISSN: 1098-4275 [Electronic] United States
• PMID: 20819899 (Publication Type: Journal Article, Practice Guideline)

Chemical References

• Glucocorticoids
• Dexamethasone
• Hydrocortisone

Topics

• Bronchopulmonary Dysplasia (drug therapy, prevention & control)
• Child Development
• Dexamethasone (adverse effects, therapeutic use)
• Glucocorticoids (adverse effects, therapeutic use)
• Humans
• Hydrocortisone (adverse effects, therapeutic use)
• Infant, Newborn
• Infant, Premature
• Infant, Premature, Diseases (drug therapy, prevention & control)